<DOC>
	<DOCNO>NCT00474903</DOCNO>
	<brief_summary>This randomized phase II trial study effect esomeprazole magnesium aspirin tissue PGE2 level compare esomeprazole placebo . This type chemoprevention treatment investigates use certain drug ass whether assist prevention cancer . The use esomeprazole magnesium without aspirin may help prevent esophageal cancer patient Barrett esophagus .</brief_summary>
	<brief_title>Esomeprazole Magnesium With Without Aspirin Preventing Esophageal Cancer Patients With Barrett Esophagus</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess effect 28 day intervention aspirin 81 mg placebo orally ( PO ) daily ( QD ) + aspirin 325 mg placebo PO QD + esomeprazole 40 mg PO BID versus aspirin 81 mg PO QD + aspirin 325 mg placebo PO QD + esomeprazole 40 mg PO BID versus aspirin 325 mg PO QD + aspirin 81 mg placebo PO QD + esomeprazole 40 mg PO BID absolute change tissue prostaglandin E2 ( PGE2 ) concentration , determine Barrett 's esophagus mucosal biopsy sample obtain pre- post-intervention ( i.e . two pair-wise comparison two different dos active aspirin regimen versus aspirin placebo group ) , Specifically , two active aspirin + esomeprazole arm independently analyze see significantly reduce mean tissue PGE2 concentration Pre- Post-intervention compare aspirin placebo + esomeprazole arm . SECONDARY OBJECTIVES : I . To determine change tissue PGE2 concentration decrease significantly aspirin placebo + esomeprazole arm . II . To compare change mean tissue PGE2 concentration two active intervention arm determine one appear promise test . III . To assess effect three agent ( arm ) respect proliferation ( Ki-67 ) , apoptosis ( caspase-3 expression ) , COX-2 expression , p16 methylation use Pre- Post-Intervention biopsy sample obtain Barrett 's mucosal tissue . IV . To evaluate adverse event associate three intervention arm . V. To provide exploratory summary PGE2 concentration value patient subgroups interest . VI . To provide descriptive summary esophagogastroduodenoscopy ( EGD ) result , rate dysplasia , adverse event , Run-In Agent compliance participant sign consent form start Run-In phase trial . VII . To establish biospecimen repository archive future correlative study . OUTLINE : This multicenter , randomize , double-blind , placebo-controlled study . Patients stratify accord dysplasia status , gender , length Barrett segment circumferential involvement ( 5 cm v = 5 cm ) . Patients randomize 1 3 treatment arm . ARM I : Patients receive two oral placebo daily oral esomeprazole magnesium twice daily . ARM II : Patients receive oral acetylsalicylic acid ( aspirin ) oral placebo daily oral esomeprazole magnesium twice daily . ARM III : Patients receive higher-dose oral aspirin ( high arm II ) lower-dose oral placebo ( low arm II ) daily oral esomeprazole magnesium twice daily . In arm , treatment continue 28 day absence unacceptable toxicity . Tissue sample collect treatment examine tissue-based biomarkers ( i.e. , PGE_2 , Ki-67 , caspase-3 apoptosis , cyclooxygenase-2 ) immunohistochemistry , enzyme immunoassay , Western blot , polymerase chain reaction . After completion study therapy , patient follow 7 - 30 day .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Histologically confirm Barrett esophagus , meet follow criterion : Presence specialize columnar epithelium anywhere tubular esophagus ≥ 2 cm circumferential involvement No evidence highgrade dysplasia cancer esophagogastroduodenoscopy ( EGD ) No prior histologically confirm esophageal dysplasia , include cancer Adequate Barrett mucosa , define ≥ 4 8 research sample with≥ 50 % intestinal metaplasia research biopsies No ulcer , erosion , plaque , nodule , stricture , luminal irregularity within Barrett 's segment erosive esophagitis ( Los Angeles classification &gt; grade A ) detect preintervention EGD exam Eastern Cooperative Group ( ECOG ) performance status 02 Hemoglobin normal Platelet count ≥ 100,000/mm³ Aspartate aminotransferase ( AST ) ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Bilirubin ≤ 2.5 time ULN Creatinine ≤ 2.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No nasal polyps associate asthma induce exacerbate aspirin No malignancy within past 5 year except nonmelanoma skin cancer No history allergic reaction attribute compound similar chemical biologic composition study agent rescue medication No history endoscopically radiographically diagnose peptic ulcer disease ( bleed nonbleeding ) No uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Bleeding disorder Vitamin K deficiency Alcohol abuse ( define ingestion ≥ 3 drink per day ) Psychiatric illness social situation would limit study compliance At least 3 month since prior chronic use ( define ≥ 7 day 3 month precede begin Runin phase ) acetylsalicylic acid ( aspirin ) , nonsteroidal antiinflammatory drug ( NSAIDs ) , selective cyclooxygenase ( COX2 ) inhibitor At least 3 month since prior investigational agent except innocuous agent know interaction study agent ( e.g. , standard dose multivitamin topical agent limited skin condition ) No prior fundoplication , bariatric surgery , major upper gastrointestinal surgery Prior cholecystectomy allow No concurrent NSAIDs ( include aspirin ) selective COX2 inhibitor therapy No concurrent anticoagulant drug include , limited , follow : Warfarin Heparin Lowmolecular weight heparin Clopidogrel bisulfate Extendedrelease dipyridamole</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>